SCHEDULE: Intracoastal Capital Group Discloses 7% Stake in Phio Pharma

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, reported a 7.0% beneficial ownership in Phio Pharmaceuticals Corp. common stock.

Summary

• Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G.
• The Reporting Persons beneficially own an aggregate of 430,000 shares of Phio Pharmaceuticals Corp. common stock.
• This ownership represents approximately 7.0% of the company's common stock.
• The 430,000 shares consist of 230,000 shares issuable upon exercise of Intracoastal Warrant 1 and 200,000 shares issuable upon exercise of Intracoastal Warrant 2.
• The calculation is based on 5,726,750 shares of common stock outstanding as of August 12, 2025, plus the 430,000 shares from the exercisable warrants.
• Additional warrants (Intracoastal Warrants 3, 4, 5, and 6) totaling 1,040,090 shares are excluded from the current beneficial ownership due to blocker provisions that prevent exercise if it would result in ownership exceeding 4.99% of the common stock.
• Without these blocker provisions, the Reporting Persons would have been deemed to beneficially own 1,480,090 shares of Common Stock.

Sentiment

Score: 6

Explanation: The filing discloses a significant beneficial ownership stake by an institutional investor group, which can be interpreted as a positive signal of confidence in the company, even though the filing itself is purely factual and does not contain operational or financial updates.

Positives

• A significant institutional investor group, Intracoastal Capital LLC, holds a 7.0% beneficial ownership stake, signaling notable investor interest.
• The potential beneficial ownership without blocker provisions is 1,480,090 shares, indicating a larger underlying interest in the company.

Future Outlook

NA

Industry Context

This filing reflects an institutional investor's position in a publicly traded pharmaceutical company. Such disclosures are standard for significant equity holdings and provide transparency regarding major shareholders, which can influence market perception within the biotechnology and pharmaceutical sectors.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant institutional ownership. The presence of a substantial investor group may be viewed positively, potentially influencing investor sentiment.
• Management: Awareness of a significant shareholder group that, while not seeking control, holds a notable stake and could potentially engage on certain matters (e.g., nominations under Rule 14a-11).

Key Dates

Keywords

Phio Pharmaceuticals Corp., Intracoastal Capital LLC, Mitchell P. Kopin, Daniel B. Asher, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Institutional Investor, Equity Stake